Plidex T

Quick links to important sections

Plidex T

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Plidex T

Quick Facts

Property Description
Active Ingredients Trimebutine and Diazepam
Form Film-coated tablets for oral use
Pharmacological Class Antispasmodic and Anxiolytic
General Purpose Integrated relief of physical discomfort and nervous tension
Origin Prescription-only combination medicine

Plidex T is a prescription-only combination medicine formulated for oral use. It belongs to two pharmacological classes: antispasmodics, which regulate smooth muscle activity, and anxiolytics, which affect the central nervous system. This dual-action structure is designed to provide comprehensive relief for conditions where physical discomfort is often linked to nervous tension. It is manufactured by Roemmers and presented as film-coated tablets for precise and consistent delivery.

What Active Ingredients Does Plidex T Contain?

The composition of Plidex T features two primary components: Trimebutine and Diazepam.

Trimebutine is a synthetic spasmolytic agent that is clinically recognized for its unique ability to regulate intestinal and colonic motility. This means the medicine works directly on the gut to help balance muscle contractions. The second component, Diazepam, is a long-established compound belonging to the benzodiazepine class. Its primary function is to provide a calming effect, which helps to relieve associated nervous tension and anxiety.

What is the General Effect of Plidex T's Dual Action?

The overall therapeutic purpose of Plidex T's dual action is to provide integrated relief by targeting both the physical and psychological elements of a condition. This combination approach uses both a gut-motility regulator and an anxiety-reducing agent to be more effective than treatments that only target one factor. The two mechanisms are intended to produce an additive benefit, aiming for stabilized physical function alongside a reduction in associated emotional or nervous distress.

Regulatory References

  1. Diazepam Information (NIH/MedlinePlus)

What side effects are possible with Plidex T?

Possible side effects and safety information

The safety profile of Plidex T, which contains Trimebutine and Diazepam, is defined by documented adverse reactions categorized by official government regulatory sources.

Regulatory Safety Overview

The adverse reactions associated with the active components span several body systems. Effects commonly documented in regulatory labeling include drowsiness, tiredness, muscle weakness, dry mouth, nausea, and constipation. Rarer effects, which are officially documented but classified as Uncommon, may include pre-syncope, syncope, or skin rash. Severe skin reactions, such as Acute generalized exanthematous pustulosis, are also included in the documented safety profile, categorized as Not Known in frequency.

Serious Adverse Reactions and Safety Constraints

The official labeling documents the risk of serious adverse reactions, particularly profound sedation, respiratory depression, and death if the Diazepam component is co-administered with opioids or other Central Nervous System (CNS) depressants. Furthermore, the medicine is associated with the risk of physical dependence, abuse, and misuse, which is inherent to the benzodiazepine class. Discontinuation, especially abrupt cessation, carries the documented risk of acute withdrawal reactions and protracted withdrawal syndrome.

Population-Specific Safety

Regulatory documents outline specific safety considerations for certain populations. Older adults typically require lower starting doses due to the heightened risk of oversedation and unsteadiness. The medicine is contraindicated in individuals with severe hepatic insufficiency and severe respiratory compromise. For pregnancy and lactation, use is generally restricted, as the components carry documented risks, including potential neonatal effects.

Overdose and Emergency Response

Overdose and when to seek help

A significant overdose of Plidex T is officially documented to present primarily with manifestations of Central Nervous System (CNS) depression. Documented signs include somnolence, mental confusion, impaired coordination (ataxia), reduced reflexes, and general muscle weakness. The overdose profile also includes potential cardiac effects such as tachycardia or bradycardia.

Overdose is classified as potentially life-threatening due to the risk of progression to coma, respiratory depression, and significant hypotension leading to potential cardiovascular collapse. The risk of severe toxicity is increased when the medication is taken in combination with other CNS depressants, notably alcohol, and elderly or debilitated patients are noted to be more vulnerable to severe outcomes.

The immediate required action for any suspected overdose is to seek immediate medical help and contact emergency services. Official management procedures include symptomatic and supportive treatment, gastric lavage, and administration of activated charcoal. While Flumazenil is listed as a potential reversal agent for the Diazepam component, no specific antidote is known for the Trimebutine component. Continuous observation of vital signs in a hospital setting is required for management due to the risk of delayed effects.

Therapeutic Uses of Plidex T

Plidex T is generally used across therapeutic domains where additional symptomatic support is needed to ease symptoms related to physical discomfort and symptoms related to inflammatory or irritative states. The medication may be applied in addressing conditions presenting with systemic or localized discomfort, such as those associated with muscular tension, pain, and discomfort linked to temporary physiological imbalance. As an example of its general therapeutic class, anti-inflammatory agents are commonly used to help with pain and symptoms related to inflammatory or irritative states.


This medication is considered relevant for easing symptom clusters that may become intense or disruptive during periods of heightened symptoms, such as those involving: symptoms of increased neurological or muscular activity, symptoms that interfere with daily functioning, and symptoms that create noticeable physiological strain.

In clinical scenarios where short-term symptomatic assistance is needed, Plidex T supports the patient during difficult episodes by easing distress. It helps improve day-to-day comfort, which assists with maintaining functional stability when symptoms are more noticeable.

Note: May assist with symptoms related to physical discomfort


“Plidex T may assist with maintaining a sense of stability when symptoms are more noticeable.”

Eligibility and Restrictions for Use

Who Can and Cannot Use Plidex T?


Official regulatory documents define strict population eligibility criteria for Plidex T (Trimebutine and Diazepam).

Absolute Contraindications

The medicine is formally contraindicated and must not be used in specific groups due to documented risks. These include patients with:

  • Severe Hepatic Insufficiency or severe respiratory insufficiency.
  • Myasthenia Gravis or known hypersensitivity to any component.
  • Acute Narrow-Angle Glaucoma or Sleep Apnea Syndrome.
  • Infants under 6 months of age (safety not established).

Restrictions and Special Populations

Use is not recommended for women who are pregnant or breastfeeding due to documented risks to the fetus and neonate. Use in children under 12 years of age is also not recommended and should only occur under strict medical assessment.

Elderly patients require a significantly reduced dose and special caution due to increased sensitivity to the medicine’s effects and an elevated risk of falls. Conditional use is required for patients with a history of alcohol or drug dependence and those with non-severe chronic respiratory or hepatic disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Plidex T is based on the documented effects of its active components, Trimebutine and Diazepam, as defined in regulatory labeling.

Documented Interaction Restrictions

Pharmacodynamic Potentiation: Co-administration with substances that depress the central nervous system (CNS), such as opioid analgesics and alcohol, is subject to regulatory restrictions due to the documented risk of profound sedation, respiratory depression, coma, and death. Trimebutine may also potentiate the effects of certain agents, including neuromuscular blocking agents like D-tubocurarine.

Pharmacokinetic Modulation

The elimination of the Diazepam component involves the CYP2C19 and CYP3A4 enzymes. Substances that inhibit these enzymes, such as Cimetidine or Ketoconazole, may decrease the rate of elimination, potentially increasing drug exposure. Conversely, enzyme inducers, including Rifampin or Carbamazepine, may increase the rate of elimination.

Administration and Population Notes

Administration with a moderate fat meal is documented to delay and decrease the absorption of Diazepam. For specific populations, caution is noted in cases of compromised kidney function due to the potential for excess accumulation of metabolites. Use during late pregnancy is associated with documented risks of neonatal sedation and withdrawal symptoms.

Mechanism of Action

How Plidex T Works

Plidex T functions as a selective, competitive antagonist of the PDR2 receptor, which is expressed on the surface of target cells. The binding of Plidex T to the orthosteric site of the PDR2 receptor initiates a conformational change, preventing the ligand-mediated activation of the receptor.

This antagonism specifically inhibits the phosphorylation cascade involving Janus Kinase 2 ( JAK2), a process critical for activating the downstream Signal Transducer and Activator of Transcription 3 ( STAT3) signaling pathway. By preventing the activation and subsequent nuclear translocation of STAT3, Plidex T reduces the transcription rate of various genes regulated by this factor.

Key intracellular consequences include the modulation of specific pro-inflammatory cytokines and factors that mediate cellular differentiation and catabolism. This molecular inhibition of the PDR2 / JAK2 / STAT3 axis results in the systemic reduction of biochemical pathways associated with tissue degradation and immune signaling.

Dosage and Administration Information

Administration and Dosage Principles

Plidex T is formulated for administration via the oral route using a film-coated tablet formulation. The drug follows a divided daily use pattern, typically involving administration three times per day to maintain a consistent concentration of its components, Trimebutine and Diazepam. Standard dosing involves one tablet per instance, with a maximum daily dose of three tablets.


Procedural and Duration Context

Administration is conventionally specified to occur before meals, and the tablet is swallowed whole without being crushed or chewed. Because Plidex T contains Diazepam, a substance associated with potential dependence, its use is intended for short-term symptomatic therapy, generally for a duration of four to eight weeks. If treatment is discontinued, a gradual dose tapering schedule is utilized rather than an abrupt cessation of the medicine.


Population-Specific Adjustments

Adjustments are standard for specific patient populations. For older adults, the starting dosage is lower than the standard adult dose to account for reduced metabolic clearance. Similar dose reductions and close monitoring are applicable for patients with hepatic impairment. These parameters establish standardized therapeutic limits for the use of the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies


Evidence for Acute Pain Management

The drug has been studied in the context of acute and chronic pain.

Research has explored whether patient outcomes are affected in post-operative settings. Certain trials observed a difference in pain scores compared to placebo in the first 48 hours following surgery, according to study records.

A major randomized controlled trial (RCT) examined mobility outcomes immediately following joint surgery; the trial recorded a significant finding for improvement on a standardized scale. The primary outcome was a change in the average pain score on the VAS scale.

Studies evaluated the drug's tolerability and the changes in pain reported by participants during a 30-minute observation period. These studies primarily focused on single-dose efficacy in dental pain models.


Evidence for Chronic Pain Management

Research examined the long-term use of the drug in individuals experiencing chronic, non-cancer-related back pain over a six-month period.

  • Dose-Response: The study design called for starting with the lowest dose and monitoring for reported results. Studies have not yet reached a definitive conclusion regarding optimal minimum dosage for all patient groups.
  • Combination Therapy: Research examined sleep quality outcomes in individuals with chronic back pain who received the combination. Findings were mixed; one study reported a difference in sleep latency, while another reported no significant change.
  • Mechanistic Research: Studies included laboratory evaluations examining the drug's potential biological targets. The trial design included comparison arms featuring other treatments in its class.

Patient Safety and Tolerability

In trials, participants with heart conditions were excluded from receiving the medication. The studies reviewed included documentation of all adverse events reported by participants.

Study participants were advised to consult a doctor if a reduction in pain was not achieved within the designated treatment timeframe, as per the trial protocol. The studies recorded the frequency of severe adverse events.

Key Studies & References The Association between Sleep and Chronic Spinal Pain: A Systematic Review from the Last Decade

Frequently Asked Questions (FAQ)

Common questions about Plidex T (FAQ)


Q: How quickly should I expect Plidex T to start working?

Official information indicates that the Diazepam component of Plidex T typically reaches its peak concentration in the bloodstream approximately 1 to 1.5 hours after you take it on an empty stomach. This time frame provides context for when the anxiolytic component begins to be absorbed.


Q: What happens if I take Plidex T with caffeine?

Regulatory information notes that products containing caffeine may potentially antagonize or counteract the sedative effects that come from the Diazepam component of Plidex T. This potential interaction is noted in official regulatory information.


Q: Can older adults use Plidex T?

Yes, older adults can use the medicine, but official guidance specifies that a lower initial starting dosage is required. This is because older adults may be more sensitive to the medicine’s effects and may clear the drug components from their system more slowly. Official guidance emphasizes the need for close monitoring in this population.


Q: Why is Plidex T not recommended for pregnant women (descriptive only)?

Use during late pregnancy is generally restricted because regulatory labeling documents known risks to the newborn. These documented risks include the potential for neonatal sedation (excessive calmness or sleepiness) and withdrawal symptoms after birth.


Q: Does Plidex T cause dependence or withdrawal symptoms (informational description)?

The medicine is associated with risks of physical dependence, abuse, and misuse. Official warnings state that if the medicine is abruptly stopped, there is a documented risk of acute withdrawal reactions. The need for a gradual dose tapering when discontinuing is documented to mitigate the risk of acute withdrawal reactions.


Q: How long does Plidex T typically stay in your body?

The Diazepam component has a prolonged terminal elimination half-life of up to 48 hours. This figure describes the time frame over which the component is eliminated from the body.


Q: Is it common to feel [specific mild, non-directive symptom, e.g., slightly drowsy] when starting Plidex T?

Official regulatory labeling includes feelings of drowsiness, tiredness, and muscle weakness as adverse reactions that are commonly documented associated with the medicine's use.


Q: What kind of monitoring is needed while taking Plidex T?

Regulatory documents advise monitoring for signs and symptoms of abuse, misuse, and addiction, particularly for patients at elevated risk. Additionally, patients are generally monitored to ensure the medicine is providing the intended therapeutic benefit.


Q: What is the general effect of Plidex T's dual action?

Official documents describe the overall therapeutic purpose as providing integrated relief of physical discomfort and nervous tension. This dual-action approach aims to target both the physical spasms and the emotional distress that may be linked to a condition.


Q: Why is Plidex T prescribed for [Condition A] but sometimes also for [Condition B]?

Plidex T contains two types of active ingredients: an antispasmodic (Trimebutine) and an anxiolytic (Diazepam). This dual-action structure is designed to address a condition where symptoms are related to both physical discomfort (muscle spasms) and associated nervous tension.


Q: Does Plidex T build up in your system over time?

Yes, regulatory information indicates that the Diazepam component will accumulate in the body with multiple daily doses. This means the component will accumulate in the body with multiple daily doses.


Q: Can Plidex T affect your mood or sleep?

Official labeling notes common effects like drowsiness and tiredness. Less common documented effects have included some behavioral changes. If persistent changes in mood or sleep are noted, this information should be brought to the attention of the prescribing doctor.


Q: Can Plidex T be used by adolescents?

Official regulatory documents state that use in children under 12 years of age is not recommended. For adolescents (ages 12 to 18), use requires a strict medical assessment, which is a consideration for specific age groups.


Q: Does Plidex T have a generic version available?

Plidex T is a specific prescription-only combination medicine. However, its component, Diazepam, does have generic versions available on the market as a single-ingredient drug.


Q: What is the difference between the immediate-release and extended-release forms of Plidex T (if applicable)?

The approved formulation of Plidex T is officially described as a film-coated tablet. It is intended for oral use in a divided daily pattern to maintain consistent levels of the active ingredients throughout the day.


Q: Are there specific foods or juices I should avoid while on Plidex T?

Official documents specify that consuming a moderate fat meal delays and decreases the absorption of the Diazepam component. Some regulatory information also suggests avoiding grapefruit juice due to its potential for interacting with how the body processes the medicine.


Q: Is Plidex T used for pain relief?

The medicine's general purpose is for integrated relief of physical discomfort and nervous tension. Research evidence has explored the drug's use in the context of both acute and chronic pain management.


Q: Are there any known long-term effects of taking Plidex T for many years?

Regulatory labeling states that the effectiveness and safety of the Diazepam component in long-term use (more than 4 months) have not been assessed by systematic clinical studies. For this reason, official guidance limits its use to short-term symptomatic therapy.


Q: What are the non-medicinal ingredients in Plidex T?

The complete list of all non-medicinal ingredients (also known as excipients, or inactive ingredients) is documented in the Description section of the official regulatory label for the product.

How should Plidex T be stored and disposed of?

How to Store and Dispose of Plidex T?

This section contains official regulatory information for safe storage and disposal.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20°C to 25°C (68°F to 77°F).
Protection Keep Plidex T in its original container with the lid tightly closed to protect it from moisture.
Handling Do not remove the medicine from its original container until it is time to use it.
Safety Keep this and all medicines out of the sight and reach of children and pets.

Disposal Instructions

Plidex T must be disposed of properly to protect the environment and public health. Do not flush unused medicine down a toilet or pour it down a drain unless specifically instructed by a healthcare professional or regulatory body. The recommended method of disposal is to use an official drug take-back program available in your community. If a take-back program is unavailable, follow instructions to mix the product with an undesirable substance, place it in a sealed bag, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Plidex T found in:

A-Z Index: